Functional Differences Between EBV- and CMV-Specific CD8⁺ T cells Demonstrate Heterogeneity of T cell Dysfunction in...

Area of Science:

• Immunology
• Oncology
• Virology

Background:

• T cell dysfunction is a key feature of chronic lymphocytic leukemia (CLL), impacting infection risk, immune surveillance, and immunotherapy outcomes.
• The precise mechanisms underlying T cell dysfunction in CLL remain incompletely understood.
• Studying T cell responses to chronic viral infections, like Epstein-Barr virus (EBV) and Cytomegalovirus (CMV), provides a model to investigate CLL's effects on antigen-specific T cells.

Purpose of the Study:

• To investigate the functional and phenotypic differences of EBV-specific CD8+ T cells in CLL patients compared to healthy controls.
• To compare the cytotoxic potential of EBV-specific and CMV-specific CD8+ T cells in the context of CLL.
• To elucidate the molecular mechanisms by which CLL influences EBV-specific T cell function through transcriptome analysis.

Main Methods:

• Phenotypic analysis of EBV-specific CD8+ T cells, including the assessment of inhibitory receptor expression.
• Evaluation of the cytotoxic potential of EBV-specific and CMV-specific CD8+ T cells from CLL patients.
• Transcriptome analysis to identify differential gene expression in EBV-specific T cells from CLL patients.

Main Results:

• EBV-specific CD8+ T cells in CLL patients displayed an advanced differentiation state with increased expression of inhibitory receptors.
• CLL-derived EBV-specific CD8+ T cells exhibited reduced cytotoxic capacity, contrasting with CMV-specific T cells.
• Transcriptome analysis revealed altered expression of genes related to synapse formation and T cell exhaustion in EBV-specific T cells, while activation and differentiation genes remained unaffected.

Conclusions:

• Antigen-specific T cell responses in CLL are heterogeneous, with EBV-specific CD8+ T cells showing distinct signs of dysfunction.
• The findings highlight altered synapse formation and T cell exhaustion pathways as key contributors to EBV-specific T cell dysfunction in CLL.
• Understanding this heterogeneity is crucial for deciphering immune dysregulation in CLL and developing effective immunotherapies.